A phase 2a study of R552 in patients with moderately to severely active rheumatoid arthritis
Latest Information Update: 05 May 2023
At a glance
- Drugs Ocadusertib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 02 May 2023 According to a Rigel Pharmaceuticals media release, the trial is expected to begin in the second quarter of 2023.
- 12 Jan 2023 New trial record
- 09 Jan 2023 According to a Rigel Pharmaceuticals media release, the study analysis is expected by the end of 2024.